Immunoprin (Azathioprine)

Azathioprine is metabolized to 6‑mercaptopurine, which blocks the synthesis of purine nucleotides. This limits DNA and RNA production in rapidly dividing cells, especially T‑ and B‑lymphocytes, thereby reducing their proliferation and overall immune activity.

The specific dose of Immunoprin is individualized by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Safety of azathioprine during pregnancy or lactation is not fully established. Physicians must weigh potential benefits against possible risks to the fetus or infant, and decisions should be made in consultation with a specialist experienced in maternal‑fetal medicine.

To place an order, submit an enquiry on the Immunoprin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine, azathioprine offers a different mechanism—purine synthesis inhibition—resulting in a distinct side‑effect profile. It is often chosen when long‑term oral therapy is needed, but the choice depends on the clinical scenario and physician judgment.

Immunoprin should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Immunoprin is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The exact administration schedule—once daily or divided doses—depends on the individual treatment plan.

The most serious risks include severe bone‑marrow suppression (myelosuppression), which can lead to infections, anemia or bleeding, and rare cases of liver toxicity or pancreatitis. Patients should undergo regular laboratory monitoring to detect these complications early.

Immunoprin is contraindicated in individuals with known hypersensitivity to azathioprine or its metabolites, those with severe liver disease, and patients who are pregnant without specialist advice. It should also be avoided in patients with active, uncontrolled infections.